» Articles » PMID: 23907568

Survivin Expression is an Independent Poor Prognostic Marker in Lung Adenocarcinoma but Not in Squamous Cell Carcinoma

Overview
Journal Virchows Arch
Date 2013 Aug 3
PMID 23907568
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Survivin is a member of the inhibitors of apoptosis and frequently overexpressed in various cancer cells. Overexpression of survivin in lung cancer cells attenuates antitumor effect of tyrosine kinase inhibitors. However, data from the previous studies on the clinicopathologic implication of survivin in non-small-cell lung carcinoma (NSCLC) are inconsistent. We investigated the expression of survivin in 373 cases of surgically resected NSCLC. Correlations between the expression of survivin and clinicopathologic, molecular features and prognostic significance were analyzed. In adenocarcinoma, the increased expression of survivin was associated with the presence of vascular invasion, lymph node metastasis, and tumor recurrences, but we didn't find any correlation with survivin expression and clinicopathological parameters in squamous cell carcinoma. Patients with high survivin expression had significantly shorter disease-free survival (DFS; 42.2 vs. 58.8 months; p = 0.001) and shorter overall survival (OS; 60.8 vs. 71.5 months; p = 0.009) than those with low survivin expression group in adenocarcinoma. In squamous cell carcinoma, the expression of survivin was not associated with prognosis of the patients (DFS; 48.9 vs. 48.7 months; p = 0.837, OS; 61.0 vs. 62.4 months; p = 0.771). Multivariate analysis confirmed that survivin was an independent poor prognostic factor in adenocarcinoma (DFS: hazard ratio (HR), 1.687; 95 % confidence interval (CI), 1.123-2.532; p = 0.012; OS: HR, 1.965; 95 % CI, 1.108-3.486; p = 0.021). There was no statistically significant difference in the expression of survivin among different molecular subgroups (p > 0.05). Our results suggest that survivin is an independent negative prognostic factor in adenocarcinoma, but not in squamous cell carcinoma. The different prognostic roles played by survivin in adenocarcinoma and squamous cell carcinoma highlights the biological differences between these two histologic types.

Citing Articles

Bioinformatics analysis of BIRC5 in human cancers.

Ye H, Ma B, Meng G, Tao S, Wang Y, Chen Z Ann Transl Med. 2022; 10(16):888.

PMID: 36111008 PMC: 9469138. DOI: 10.21037/atm-22-3496.


Pyruvate kinase M2 is a marker of poor prognosis in lung adenocarcinoma but not lung squamous cell carcinoma.

Zhang J, Zhang C, Liu X, Sun N, Zhang C, Li R Transl Cancer Res. 2022; 9(5):3293-3302.

PMID: 35117696 PMC: 8798821. DOI: 10.21037/tcr.2020.04.23.


Clinicopathological and Prognostic Significance of Inhibitor of Apoptosis Protein (IAP) Family Members in Lung Cancer: A Meta-Analysis.

Fung S, Knoefel W, Krieg A Cancers (Basel). 2021; 13(16).

PMID: 34439255 PMC: 8392569. DOI: 10.3390/cancers13164098.


Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Puskas R, Bikov A, Horvath P, Lazar Z, Kunos L, Nagy R Pathol Oncol Res. 2021; 27:631969.

PMID: 34257598 PMC: 8262151. DOI: 10.3389/pore.2021.631969.


Comprehensive analysis of spread through air spaces in lung adenocarcinoma and squamous cell carcinoma using the 8th edition AJCC/UICC staging system.

Jia M, Yu S, Yu J, Li Y, Gao H, Sun P BMC Cancer. 2020; 20(1):705.

PMID: 32727513 PMC: 7391600. DOI: 10.1186/s12885-020-07200-w.


References
1.
Rosato A, Menin C, Boldrin D, Santa S, Bonaldi L, Scaini M . Survivin expression impacts prognostically on NSCLC but not SCLC. Lung Cancer. 2012; 79(2):180-6. DOI: 10.1016/j.lungcan.2012.11.004. View

2.
Kim H, Yoo S, Choe J, Paik J, Xu X, Nitta H . Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol. 2011; 6(8):1359-66. DOI: 10.1097/JTO.0b013e31821cfc73. View

3.
Singhal S, Vachani A, Antin-Ozerkis D, Kaiser L, Albelda S . Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res. 2005; 11(11):3974-86. DOI: 10.1158/1078-0432.CCR-04-2661. View

4.
Shinohara E, Hallahan D, Lu B . The Use of Antisense Oligonucleotides in Evaluating Survivin as a Therapeutic Target for Radiation Sensitization in Lung Cancer. Biol Proced Online. 2004; 6:250-256. PMC: 524213. DOI: 10.1251/bpo95. View

5.
Nakanishi K, Kawai T, Kumaki F, Hiroi S, Mukai M, Ikeda E . Survivin expression in atypical adenomatous hyperplasia of the lung. Am J Clin Pathol. 2003; 120(5):712-9. DOI: 10.1309/GWTN-2JTA-N6K7-3YDE. View